BIOMAT Database Logo BIOMAT Database Logo

Nonresponsiveness of brain tumors to VM-26 therapy in children. 1979

M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer

UI MeSH Term Description Entries
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013713 Teniposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. Demethyl Epipodophyllotoxin Thenylidine Glucoside,NSC-122819,Teniposide, (5a alpha,9 alpha(S*))-Isomer,VM-26,Vumon,NSC 122819,NSC122819,VM 26,VM26
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
Teniposide (VM-26) in brain tumors.
April 1992, Seminars in oncology,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children.
March 1980, Helvetica paediatrica acta,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
Iv methyl-CCNU, VM-26, and cranial irradiation in therapy for malignant brain tumors.
December 1977, Cancer treatment reports,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
March 1979, Surgical neurology,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
[Hypersensitivity to VM-26].
January 1984, Klinische Padiatrie,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
[Allergic reactions to teniposide (VM-26) in children with neoplasms].
February 1992, Wiadomosci lekarskie (Warsaw, Poland : 1960),
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
Immunologic nonresponsiveness to tumors.
January 1998, Critical reviews in oncogenesis,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children.
January 1988, The American journal of pediatric hematology/oncology,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
April 2007, Journal of neuro-oncology,
M P Sullivan, and J van Eys, and J Herson, and K A Starling, and A Ragab, and C Sexhauer
VM-26 as a second drug in the treatment of brain gliomas.
March 1979, Cancer treatment reports,
Copied contents to your clipboard!